![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PSMC3 |
Gene summary for PSMC3 |
![]() |
Gene information | Species | Human | Gene symbol | PSMC3 | Gene ID | 5702 |
Gene name | proteasome 26S subunit, ATPase 3 | |
Gene Alias | DCIDP | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A140VK42 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5702 | PSMC3 | GSM4909281 | Human | Breast | IDC | 4.96e-02 | 2.22e-01 | 0.21 |
5702 | PSMC3 | GSM4909288 | Human | Breast | IDC | 2.74e-02 | 1.35e-01 | 0.0988 |
5702 | PSMC3 | GSM4909296 | Human | Breast | IDC | 1.21e-05 | -2.65e-02 | 0.1524 |
5702 | PSMC3 | GSM4909297 | Human | Breast | IDC | 2.51e-09 | -7.98e-02 | 0.1517 |
5702 | PSMC3 | GSM4909311 | Human | Breast | IDC | 2.23e-22 | -2.06e-01 | 0.1534 |
5702 | PSMC3 | GSM4909312 | Human | Breast | IDC | 2.10e-09 | -8.23e-02 | 0.1552 |
5702 | PSMC3 | GSM4909319 | Human | Breast | IDC | 2.77e-27 | -1.52e-01 | 0.1563 |
5702 | PSMC3 | GSM4909320 | Human | Breast | IDC | 3.12e-02 | -1.96e-01 | 0.1575 |
5702 | PSMC3 | GSM4909321 | Human | Breast | IDC | 2.97e-08 | -3.14e-03 | 0.1559 |
5702 | PSMC3 | brca1 | Human | Breast | Precancer | 6.32e-26 | 6.42e-01 | -0.0338 |
5702 | PSMC3 | brca2 | Human | Breast | Precancer | 2.29e-18 | 5.20e-01 | -0.024 |
5702 | PSMC3 | brca3 | Human | Breast | Precancer | 1.56e-03 | 1.62e-01 | -0.0263 |
5702 | PSMC3 | NCCBC14 | Human | Breast | DCIS | 6.14e-05 | -9.03e-02 | 0.2021 |
5702 | PSMC3 | NCCBC2 | Human | Breast | DCIS | 6.02e-04 | -2.43e-01 | 0.1554 |
5702 | PSMC3 | NCCBC5 | Human | Breast | DCIS | 1.08e-11 | 1.35e-01 | 0.2046 |
5702 | PSMC3 | P1 | Human | Breast | IDC | 2.29e-13 | -1.43e-01 | 0.1527 |
5702 | PSMC3 | P2 | Human | Breast | IDC | 1.03e-03 | 2.19e-01 | 0.21 |
5702 | PSMC3 | DCIS2 | Human | Breast | DCIS | 1.44e-50 | 1.29e-01 | 0.0085 |
5702 | PSMC3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.21e-11 | 2.34e-01 | -0.1808 |
5702 | PSMC3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.88e-11 | 3.37e-01 | -0.0811 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006113633 | Thyroid | ATC | regulation of proteasomal protein catabolic process | 128/6293 | 187/18723 | 1.63e-22 | 4.30e-20 | 128 |
GO:0045732210 | Thyroid | ATC | positive regulation of protein catabolic process | 148/6293 | 231/18723 | 1.93e-21 | 4.36e-19 | 148 |
GO:190336434 | Thyroid | ATC | positive regulation of cellular protein catabolic process | 109/6293 | 155/18723 | 8.26e-21 | 1.49e-18 | 109 |
GO:190180027 | Thyroid | ATC | positive regulation of proteasomal protein catabolic process | 85/6293 | 114/18723 | 3.70e-19 | 5.20e-17 | 85 |
GO:190305227 | Thyroid | ATC | positive regulation of proteolysis involved in cellular protein catabolic process | 93/6293 | 133/18723 | 1.06e-17 | 1.18e-15 | 93 |
GO:004586234 | Thyroid | ATC | positive regulation of proteolysis | 202/6293 | 372/18723 | 1.07e-16 | 9.42e-15 | 202 |
GO:001908023 | Thyroid | ATC | viral gene expression | 64/6293 | 94/18723 | 8.44e-12 | 3.16e-10 | 64 |
GO:004440334 | Thyroid | ATC | biological process involved in symbiotic interaction | 153/6293 | 290/18723 | 1.12e-11 | 4.12e-10 | 153 |
GO:005181721 | Thyroid | ATC | modulation of process of other organism involved in symbiotic interaction | 50/6293 | 81/18723 | 2.01e-07 | 3.17e-06 | 50 |
GO:001908322 | Thyroid | ATC | viral transcription | 33/6293 | 50/18723 | 2.83e-06 | 3.26e-05 | 33 |
GO:005185121 | Thyroid | ATC | modulation by host of symbiont process | 37/6293 | 60/18723 | 7.87e-06 | 8.04e-05 | 37 |
GO:003582121 | Thyroid | ATC | modulation of process of other organism | 55/6293 | 106/18723 | 7.71e-05 | 5.82e-04 | 55 |
GO:004478821 | Thyroid | ATC | modulation by host of viral process | 18/6293 | 30/18723 | 2.71e-03 | 1.24e-02 | 18 |
GO:005170222 | Thyroid | ATC | biological process involved in interaction with symbiont | 45/6293 | 94/18723 | 2.86e-03 | 1.30e-02 | 45 |
GO:004392211 | Thyroid | ATC | negative regulation by host of viral transcription | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0305010 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
hsa0501714 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0305013 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
hsa0501715 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PSMC3 | SNV | Missense_Mutation | novel | c.427N>C | p.Glu143Gln | p.E143Q | P17980 | protein_coding | tolerated(0.11) | benign(0.157) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PSMC3 | SNV | Missense_Mutation | c.149N>A | p.Ser50Asn | p.S50N | P17980 | protein_coding | tolerated(1) | benign(0.001) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PSMC3 | SNV | Missense_Mutation | c.874N>A | p.Gly292Ser | p.G292S | P17980 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A1HE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PSMC3 | SNV | Missense_Mutation | c.73N>A | p.Glu25Lys | p.E25K | P17980 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
PSMC3 | SNV | Missense_Mutation | novel | c.532N>C | p.Asp178His | p.D178H | P17980 | protein_coding | deleterious(0.02) | probably_damaging(0.97) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
PSMC3 | SNV | Missense_Mutation | c.73N>A | p.Glu25Lys | p.E25K | P17980 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
PSMC3 | SNV | Missense_Mutation | rs771618920 | c.329A>G | p.Asn110Ser | p.N110S | P17980 | protein_coding | tolerated(0.2) | benign(0) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PSMC3 | SNV | Missense_Mutation | c.380N>T | p.Ser127Phe | p.S127F | P17980 | protein_coding | deleterious(0) | possibly_damaging(0.868) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
PSMC3 | SNV | Missense_Mutation | novel | c.375N>C | p.Lys125Asn | p.K125N | P17980 | protein_coding | deleterious(0.04) | possibly_damaging(0.535) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PSMC3 | SNV | Missense_Mutation | c.1178N>A | p.Gly393Glu | p.G393E | P17980 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5702 | PSMC3 | NA | inhibitor | BORTEZOMIB | BORTEZOMIB | |
5702 | PSMC3 | NA | inhibitor | CARFILZOMIB | CARFILZOMIB | |
5702 | PSMC3 | NA | inhibitor | CHEMBL2103884 | OPROZOMIB | |
5702 | PSMC3 | NA | inhibitor | CHEMBL451887 | CARFILZOMIB | |
5702 | PSMC3 | NA | BORTEZOMIB | BORTEZOMIB | 24524217 | |
5702 | PSMC3 | NA | inhibitor | CHEMBL325041 | BORTEZOMIB | |
5702 | PSMC3 | NA | CARFILZOMIB | CARFILZOMIB | 24524217 | |
5702 | PSMC3 | NA | inhibitor | CHEMBL3545432 | IXAZOMIB CITRATE |
Page: 1 |